检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:Rong Li Hongping Zhang Qingshui Li Guangwen Yuan Yanjie Zhou Rutie Yin He Wang Chunyan Wang Yi Huang Wei Wang Xiaojian Yan Lingying Wu Qi Zhou
机构地区:[1]The Gynecologic Oncology Center,Chongqing University Cancer Hospital,Chongqing,China [2]Department of Gynecologic,Yunnan Cancer Hospital,Kunming,China [3]Department of Gynecologic Oncology,Shandong Cancer Hospital,Jinan,China [4]Department of Gynecologic Oncology,Cancer Hospital,Chinese Academy of Medical Sciences,Beijing,China [5]Department of Gynecologic Oncology,Hunan Cancer Hospital,Changsha,China [6]Department of Tumor Radiotherapy and Chemotherapy,West China Second University Hospital of Sichuan University,Chengdu,China [7]Department of Gynecologic,Guangxi Cancer Institute,Nanning,China [8]Department of Gynecologic Oncology,Liaoning Cancer Hospital,Shenyang,China [9]Department of Gynecologic Oncology,Hubei Cancer Hospital,Wuhan,China [10]The Gynecologic Oncology Center,Peking Union Medical College Hospital,Beijing,China [11]Department of Gynecologic,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China
出 处:《Journal of the National Cancer Center》2024年第2期135-141,共7页癌症科学进展(英文)
基 金:funded by the Optimization Study of Treatment Regimen and Clinical Practice in Ovarian Cancer(grant number:2016YFC1303702).
摘 要:Background:The paclitaxel liposome formulation,encapsulating paclitaxel within a phospholipid bilayer,ad-dresses the insolubility of traditional paclitaxel formulations,thereby reducing toxicity without compromising its antitumor efficacy.Methods:This multicenter,open-label,non-inferiority randomized controlled trial(ChiCTR2000038555)evalu-ates the efficacy and safety of paclitaxel liposome in comparison to the standard regimen of paclitaxel combined with carboplatin(PLC vs.PC)as first-line therapy in patients with epithelial ovarian cancer.Results:An analysis of median progression-free survival(PFS)revealed non-inferior outcomes between 263 pa-tients in the PLC group and 260 patients in the PC group(32.3 vs.29.9 months,hazard ratio[HR],0.89[95%CI,0.64−1.25]),using a non-inferior margin of 1.3.Although the overall incidence of treatment-related adverse events was comparable between groups,the PLC group experienced significantly fewer non-hematologic toxicities than those treated with the PC regimen.Conclusion:The findings affirm the non-inferiority of paclitaxel liposome compared to the combination of pa-clitaxel and carboplatin regarding therapeutic efficacy,with an enhanced safety profile marked by reduced non-hematologic toxicities.
关 键 词:Ovarian cancer Paclitaxel liposome First-line chemotherapy Efficacy Safety
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.120